Biotech investors tend to focus on small-cap companies in search of the next big breakthrough. Still, one established player ...

Gilead's anti-viral remdesivir gets FDA emergency use authorisation for treatment of COVID-19. US-based biopharmaceutical ...

Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV prevention.

Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...

Gilead CEO Daniel O'Day discusses the FDA's emergency use authorization of remdesivir as a potential COVID-19 treatment on the White House on Friday, May 1.

A large U.S. drugmaker is partnering with Gilead Sciences to manufacture the latter company’s antiviral drug for treating Covid-19. “From the beginning, it was clear that no one company or ...

Gilead also is testing remdesivir in a separate study of moderately ill coronavirus patients. No results have yet been announced from that study, which does have a comparison group.

Remdesivir (Veklury, Gilead) was found to reduce some COVID-19 patients' risk of hospitalization by 87% in a phase 3 trial, the drug's manufacturer announced Wednesday in a press release.